June 2024

DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide Data Presented at the ADA 84th Scientific Sessions CAMBRIDGE, Mass., June 22, 2024  /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRB

GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved gluco-metabolic parameters over a 4-week treatment period in individuals with obesity, even in the lowest dosing regimen.GL0034 demonstrated gluco-metabolic activity and reductions in lipid levels, including t

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: